Answers are grounded in this paper and cite their sources.
// Hanna Engqvist 1 , Toshima Z. Parris 1 , Elisabeth Werner Rönnerman 1, 2 , Elin M.V. Söderberg 3 , Jana Biermann 1 , Claudia Mateoiu 2 , Karin Sundfeldt 4 , Anikó Kovács 2 , Per Karlsson 1, * and Khalil Helou 1, * 1 Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2 Sahlgrenska University Hospital, Department of Clinical Pathology and Genetics, Gothenburg, Sweden 3 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 4 Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden * These authors have contributed equally to this work Correspondence to: Hanna Engqvist, email: hanna.engqvist@gu.se Keywords: ovarian cancer; diagnostic biomarker; prognostic biomarker; genomics Received: June 13, 2018 Accepted: September 01, 2018 Published: October 12, 2018 ABSTRACT Ovarian cancer is the most lethal gynecological malignancy in the western world. Despite recent efforts to characterize ovarian cancer using molecular profiling, few targeted treatment options are currently available. Here, we examined genetic variants, fusion transcripts, SNP genotyping, and gene expression patterns for early-stage (I and II) ovarian carcinomas (n=96) in relation to clinicopathological characteristics and clinical outcome, thereby identifying novel genetic features of ovarian carcinomas. Furthermore, mutation frequencies of specific genetic variants and/or their gene expression patterns were associated with histotype and overall survival, e.g. SLC28A2 (mucinous ovarian carcinoma histotype), ARCN1 (low expression in 0-2 year survival group), and tumor suppressor MTUS1 (mutation status and overall survival). The long non-coding RNA MALAT1 was identified as a highly promiscuous fusion transcript in ovarian carcinoma. Moreover, gene expression deregulation for 23 genes was associated with tumor aggressiveness. Taken together, the novel biomarkers identified here may improve ovarian carcinoma subclassification and patient stratification according to histotype and overall survival.
No takes yet. Share an insight, caveat, or question.
Engqvist et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: